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A series of well designed, well conducted, drug company-sponsored
randomized studies have first demonstrated the value of CPT-11 as
second line treatment of patients with advanced colorectal cancer
(CRC) (Cunningham et al, 1998; Rougier et al, 1998) and subse-
quently the value of CPT-11+ FU in the front line treatment of this
disease (Douillard et al, 2000; Saltz et al, 2000). FDA has thus
recently approved CPT-11 for this indication. Oxaliplatin is some-
what behind CPT-11, but it elicits similar optimism among oncol-
ogists, particularly in Europe (Maindrault et al, 1999; Giachetti
et al, 2000). 
The enthusiasm about these combinations and the pressure of
drug companies is such that medical oncologists practising in the
community, outside clinical trial settings, have a very hard time
advising more conservative chemotherapy regimens to their
patients. And the cost of treating this disease will increase dramat-
ically in the next years. 
While from a research prospective the small improvements
afforded by the two new agents, particularly CPT-11, must be
greeted as major breakthroughs, caution must be exercised from a
broader perspective. The very small (<3 months) advantage in
survival for CPT-11 + FU combination vs FU alone, must be
weighed against the increased toxicity and cost of the combina-
tions. Therefore on one side the ongoing research on how to best
combine the different new agents must be enthusiastically sup-
ported, on the other, the search for alternative regimens of low cost
and toxicity must not be discouraged. 
In the mid 1990s, when biochemical modulation of FU was still
dominating the scene of CRC treatment we developed the concept
of schedule-specific biochemical modulation (Sobrero et al, 1997).
We demonstrated that the fluoropyrimidine has different mecha-
nisms of action depending on the dose schedule (Sobrero et al,
1993) and suggested that biochemical modulators should be
specific for each schedule. A hybrid regimen alternating 2
biweekly cycles of sequential MTX ® bolus FU, with a 3-week
continuous infusion of FU+LV was tested in 2 phase II clinical
studies (Sobrero et al, 1995; Aschele et al, 1998) and then 
demonstrated to be superior to modulated bolus FU in a 
recently published randomized trial (Sobrero et al, 2000). 
Based upon a British report (Ross et al, 1997) on the efficacy of
mitomycin C added to CI FU, mito was added to the infusional
part of our regimen in a phase II study that is the matter of this
report. 
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Summary We have reported that an alternating regimen of bolus and continuous infusion 5-fluorouracil (FU) was superior to bolus FU in
terms of response rate and progression-free survival in advanced colorectal cancer. Biochemical modulation was an essential part of this
regimen and it was selective for the schedule of FU administration: bolus FU was in fact modulated by methotrexate (MTX) while continuous
infusion FU was potentiated by 6-s-leucovorin (LV). Considering the low cost and the favourable report on the activity of mitomycin C (mito)
added to CI FU, we have incorporated this agent in the infusional part of our treatment programme. 105 patients with untreated, advanced,
measurable colorectal cancer were accrued from 13 Italian centres and treated with the following regimen. 2 biweekly cycles of FU bolus (600
mg/m2), modulated by MTX (24 h earlier, 200 mg/m2) were alternated with a 3-week continuous infusion of FU (200 mg/m2 daily), modulated
by LV (20 mg/m2 weekly bolus). Mito, 7 mg/m2, was given on the first day of the infusional period. After a 1 week rest, the whole cycle 
(8 weeks) was repeated, if indicated. 5 complete and 34 partial responses were obtained (response rate, 37% on the intention to treat basis;
95% confidence limits, 28–46%). After a median follow-up time of 26 months, 37 patients are still alive. The median progression-free survival
is 7.7 months with an overall survival of 18.8 months and a 2-year survival rate of 30%. The regimen was very well tolerated with fewer than
13% of patients experiencing WHO grade III–IV toxicity. These results are consistent with those obtained by our group in 3 previous trials of
schedule specific biochemical modulation of FU. They also indicate a highly active, little toxic, inexpensive regimen of old drugs to be used 
(a) as an alternative to the more expensive combinations including CPT-11 or oxaliplatin or (b) as the basis for combination programmes with
these agents. © 2001 Cancer Research Campaign http://www.bjcancer.com
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Eligibility criteria 
105 patients satisfying all of the following requirements were
accrued into this 3 institution phase II trial between August 1997
and March 1999. (1) They had to have biopsy-proven relapsed or
metastatic adenocarcinoma of the colon or rectum. There were 3
exceptions to the requirement for histologic confirmation of
metastatic disease in patients with a history of resection for
colorectal cancer no longer than 5 years before: (a) patients with 2
or more pulmonary nodules enlarging on serial chest X-rays and
no other disease site accessible to biopsy. (b) Patients with 2 or
more hepatic nodules and CEA >10 ng ml–1 in at least 2 consecu-
tive determinations; (c) patients with pelvic mass and new onset
presacral pain. (2) The disease had to be measurable. Appropriate
radiologic examinations (mostly CT scans) had to be obtained no
longer than 1 month before the beginning of treatment to serve 
as a baseline for serial evaluation of the patient’s disease status. 
(3) No prior chemotherapy for metastatic disease was allowed.
Adjuvant chemotherapy was not an exclusion criterion provided
that treatment was completed longer than 6 months before study
entry. Radiation therapy was allowed as long as it did not encom-
pass the indicator lesions. (4) ECOG performance status had to be
≤ 2. Serum bilirubin and creatinine levels were required to be less
than 3.0 and 1.7, respectively, and aspartate and alanine amino-
transferases less than 3 times the upper limits of normal. Granu-
locyte counts of greater than 1500/mm3 and platelet counts of
greater than 100 000/mm3 were required. 
Additional eligibility criteria included geographic accessibility,
the absence of clinically relevant ascites and the absence of other
medical conditions clearly contraindicating the delivery of any
chemotherapy. 
Staging should be performed within 1 month before study entry
by means of clinical assessment, blood cell count, bilirubine and
creatinine levels, transaminases, alkaline phosphatase, serum
CEA, chest X-ray or thoracic CT scan, abdominal US, CT scan or
NMR. Any imaging investigation that was abnormal due to malig-
nant disease was repeated at 2-month intervals for the duration of
treatment. 
Informed consent was required. Before treatment, patients were
informed as to: (a) the presence of metastatic colorectal cancer; 
(b) the poor prognosis of their disease; and (c) the experimental
nature of this treatment protocol. Upon study entry all patients
were given a schedule of drug treatment along with written infor-
mation about the anticipated toxicities. 
Treatment plan 
The backbone of the regimen consisted of the alternating regimen
of bolus and infusional FU that we previously tested in a phase II
trial and that was derived from 2 well studied regimens: sequential
MTX and bolus FU (Marsh et al, 1991) and CI FU modulated by
LV (Leichman et al, 1993). Mito was added to the infusional part.
Figure 1 illustrates the regimen. One complete cycle of treatment
consisted of 2 MTX ® FU bolus treatments (200 mg/m2 ® 600
mg/m2, respectively) given on days 1, 2 and 15, 16 along with LV
rescue (15 mg) given p.o. q 6 hours ´ 6 doses, followed by 3
weeks of CI FU (200 mg/m2) given from day 29 to day 49, modu-
lated by weekly LV (20 mg/m2). Mito, 7 mg/m2, was administered
once on the first day of the infusional period only. After one week
of rest, the 2nd cycle was started on day 57, provided that the
patient had recovered from toxicity. The entire duration of the
cycle is thus 8 weeks. CI FU was administered through implanted
catheters and a venus Port-a-cath (Pharmacia) connected to a
portable programmable external pump (CADD-1, Pharmacia) or
disposable elastomeres (Baxter). The infusional cassettes or elas-
tomeres were changed weekly if no toxicity developed earlier. 
Toxicity was evaluated on days 15, 29, 36, 43, 50 and 57.
Complete blood counts were obtained on the same days. Liver
function tests, blood urea nitrogen, creatinine and electrolytes
were obtained monthly. 
Dose modification criteria for the MTX®FU regimen were as
follows: no dose reduction for gastrointestinal grade I and II toxi-
city. For grade III diarrhoea or mucositis, the treatment was
delayed until recovery and the doses of MTX and FU of the next
cycle were decreased by 50%. The dose was reduced by 50% also
for a WBC of <3000/mm3 or platelets <75000/mm3 on the day 
of recycling. Treatment was discontinued in cases of grade IV
toxicity. 
CI FU was discontinued upon the first signs of mucositis and/or
palmar-plantar dysaesthesia/burning, and resumed when these
symptoms abated. In the case of severe (grade III) mucositis, the
infusion was resumed at a reduced FU dose (50%). The dose of
mito and that of LV during the infusional treatment were not modi-
fied in this study. Toxicity is expressed according to WHO criteria. 
Due to the long duration of chemotherapy cycles (2 months), the
response was evaluated after each cycle of treatment. 
The duration of treatment depended on outcome. Upon docu-
mentation of CR, 2 additional cycles were given (4 additional
months of treatment). In the case of a PR, treatment was continued
until 2 consecutive CT scans, obtained 2 months apart, failed to
demonstrate further tumour shrinkage. At that point, chemo-
therapy was stopped and the disease was monitored every 2
months. The same regimen was resumed upon documentation of
tumour progression. In patients with disease stabilization, treat-
ment was continued until evidence of progression was observed.
No guidelines were given as regarded second line chemotherapy. 
Response evaluation 
Patients who received at least 2 months of therapy (1 cycle) with
adequate pretreatment and follow-up radiographic studies
were considered assessable for response, as were patients who
experienced rapid disease progression after at least 2 courses
of bolus FU. 
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Figure 1 Design of drug regimen. One cycle = 8 weeks. In the first part of
the cycle, patients were given MTX 200 mg/m2 i.v. diluted in 500 ml D5W,
infused in 1 h, day 1; FU 600 mg/m2 i.v. bolus, day 2; (6S)LV, 15 mg p.o.
every 6 h ´ 6, days 2–3, starting after FU bolus. In the second part of the
cycle, patients were given FU, 200 mg/m2/day CI ´ 3 weeks, and LV, 
20 mg/m2 i.v. bolus every week. Mito at 7 mg/m2 was given on the first day 
of the infusional period Measurable tumour was defined as a tumour mass that could be
clearly measured in 2 dimensions by adequate imaging techniques. 
A CR was defined as complete disappearence of all evidence 
of tumour and return of abnormal tests to normal levels for a
minimum of 8 weeks. A PR was defined as a 50% or greater reduc-
tion in the sum of the products of the largest perpendicular diame-
ters of all measured lesions, in the absence of progression of any
lesion or the appearance of any new lesion for at least 8 weeks.
Stable disease was defined as too small a change in measurable
disease to meet the requirements for PR or progression, without
the appearance of new lesions for a period of at least 8 weeks,
provided that there was no worsening of symptoms. Disease
progression was defined as the development of new areas of
malignant disease, or an increase by at least 25% in the baseline
area of the measured lesions in nonresponding patients, or a 25%
increase in the size of measured lesions over that attained at best
response. Indicator lesions were measured at each successive
cycle. The baseline tumour areas and their variations at each
successive evaluation were expressed in cm2. 
PFS and and overall survival were measured from the date of
randomization to the date of disease progression as defined above,
or to the date of death, respectively and calculated using the
Kaplan–Meier method (Kaplan and Meier, 1958). Early progres-
sions and deaths, toxic deaths if any, early withdrawals and deaths
from other causes were included as failures. 
The association between performance status and the proportion
of responses were assessed using the Mantel test for trend (Mantel,
1963). 
Statistical methods 
The general philosophy behind this phase II study was that mito
should add some further activity to our alternating bolus-infusional
modulated FU regimen. The new combination would be regarded
as promising if an additional 10% response rate is added to our
basic regimen. Since our standard alternating regimen without
mito affords 30–35% RR, we were searching for a range of activity
around 40 to 45% to consider the new combination for a new
phase III study. 
According to the two stage Simon’s design, setting P0 = 30%
and P1 = 45%, with an alfa error = 0.05 (reflecting the chances to
accept an ‘inactive’ regimen) and a beta error = 0.1 (reflecting the
chances of accepting as ‘active’ a truly inactive regimen), the treat-
ment will be discontinued if less than 27 responses will be
observed among the first 77 patients. Otherwise we will proceed to
the second stage, where 33 responses over 88 patients will be
necessary to define the study successful and proceed further with
the clinical development of this combination. 
RESULTS 
Patients characteristics 
Between August 1997 and March 1999, 105 patients meeting the
eligibility criteria were registered from thirteen participating insti-
tutions. 
Table 1 shows patient characteristics. 93% of patients had had
surgery on the primary neoplasm. 20% patients had received prior
adjuvant chemotherapy: 9 received FU+LV, 10 FU-levamisol and
2 FU-LV-levamisol. The median time between diagnosis of
metastatic disease and study entry was 34 days. The wide range 
(3 to 273 days) of this figure is due to occasional patients with a
very long natural history of their disease without treatment prior to
study entry. 
The minimum size of a measurable lesion was 1 cm ´ 1 cm.
Lesions were measured by CT scan in 85 patients and ultrasound
in 12 patients, the remaining being measured by CXR and NMR.
Only 9 patients had lesions smaller than 2 cm ´ 2 cm and the
median measured baseline tumour area was 22 cm2 (range 1–194). 
Treatment outcome 
6 patients were not evaluable for response. This was due to rapid
clinical deterioration in 3 patients not allowing completion of the
first cycle of treatment, 1 refusal to continue after the first drug
administration, and lack of baseline tumour measurement in 2
patients. According to the intention-to-treat principle, all these
patients were included in the analysis of response as failures, and
in the PFS and survival analysis. 
5 complete and 34 partial responses were obtained (response
rate, 37% on the intention to treat basis; 95% confidence limits,
28–46%). In addition, a substantial percentage of patients (42%)
had stable disease (Table 2). 22 failures were reported: 15 patients
progressed after the first cycle of treatment, 3 patients showed 
a rapid disease progression before the end of the first cycle, 
2 refused to continue treatment (1 just after the first drug 
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Table 1 Baseline patient characteristics 
N 105 
Median age (range) 61 (39–77) 
Male (%) 60 
Female (%) 40 
ECOG performance status, %
0 75 
1 18 
27  
Symptomatic (%) 35 
Primary tumour site (%)
Colon 78 
Rectum 27 
Number of organs involved (%)
1 71 
2 26 
³34  
Site of metastases (%)
Liver 50 
Lung 11 
Peritoneum/nodes 10 
Prior adjuvant chemotherapy (%) 21 
Median number of lesions measured per patient (range) 3 (1–12) 
Median baseline tumor area, cm2 (range) 22 (2–194) 
Median baseline LDH (range) 414 (90–1690) 
Median baseline WBC ´ 1000 (range) 7.3 (3.7–17.1) 
Median baseline CEA level 21 (1–3835) 
Table 2 Response to treatment: intention to treat analysis 
n = 105 
Complete responses 5 (5%) 
Partial responses 34 (32%) 
Stable disease 44 (42%) 
Failures 22 (21%) 
Response rate (95% CL) 37% (28–46) administration, the other after the first cycle), and 2 had baseline
tumour measurements missing. 90% of the cases of progression
were due to the appearance of new lesions rather than enlargement
of the indicator lesion. 
The median time to achieve a partial or complete response was
61 (range, 49–246) days, with initial responses attained after one
cycle (6 cases), 2 cycles (14 cases), 3 cycles (14 cases), 4 cycles (5
cases). The median number of cycles to obtain a CR was 3. Half of
the responding patients showed continued tumour shrinkage and
the median time to achieve the maximum clinical response was
132 (range 54–545) days. Among responding patients, the median
maximum tumour mass reduction compared to the baseline
measured tumour area was 74%, while among all 105 patients this
value was 30%. 
Patients obtaining a CR had a very low measured baseline
tumour mass (median 3.2 cm2, range 1.5 to 6.7). 4 out of 5 patients
with complete response had liver disease only with multiple inop-
erable metastases (2, 3, 3 and 6 measured lesions, respectively);
the other patient had 3 lung lesions as the only site of metastatic
disease. None of these patients had received adjuvant
chemotherapy and all had baseline CEA level < than the median
value of the study population (21 ng ml–1). 
None of the patients on this study underwent surgical explo-
ration in order to resect residual disease. 
Only 8 of the 39 responses were obtained in patients with
multiple metastatic sites, the rest being liver only (22 patients),
lung only (5 patient) and extrahepatic intra-abdominal disease
(4 patients). However the % RR in patients with 1 metastatic site
(n = 80) was similar to that observed in patients with 2 or more
metastatic sites (n = 25) (39% vs 32% P = NS). 
The baseline CEA level did not appear to influence the response
rate (36% vs. 44%, in patients with CEA levels above or below 
5n gm l –1; P = NS). 
The overall response rate was similar in patients with either
colon (29 of 78 patients, 37%) or rectal primaries (10 of 27
patients, 37%). 
Previous adjuvant treatment appeared to influence the clinical
response but the difference did not reach statistical significance: 
6 of 21 patients who had received adjuvant treatment responded
(29% response rate) while 33 responses were observed among the
84 patients who had not received prior adjuvant chemotherapy
(39% response rate). 
The combined CR and PR rate was 41%, both in patients with
an ECOG PS of 0 and 1. Symptomatic patients responded in 41%
and asymptomatic in 40%. 
Age and sex did not appear to influence the overall clinical
response. 33% in < 60 vs 44 in > 60, P = NS, male 36%, female
45%. 50% of symptomatic patients (n = 42) improved their symp-
toms after the first cycle of treatment while only 13% got worse
subjectively, the rest being stable. 
The median duration of response was 8.1 (range, 2–21) months
and the median duration of stable disease was 6.4 (range, 1–20)
months. All patients are now off treatment. 
3 patients declined further chemotherapy while they were still
responding; they were considered treatment failures as of the date
the treatment was discontinued. After a median follow-up time of
26 months, 95 patients have progressed and 37 patients are still
alive. The median progression-free survival was 7.7 months
(Figure 2) with an overall survival of 18.8 months and a 2-year
survival rate of 30% (Figure 3). 
Safety 
273 cycles of treatment (2 months each) were administered, with a
median of 3 cycles (range, 0–6) per patient. 
Table 3 reports the worst toxicity of each type, suffered by each
patient, across all cycles. The 2 parts of the regimen are considered
separately. 538 cycles of sequential MTX®FU and 711 weeks of
CI FU are the denominator of these percentages. No toxic deaths
1026 A Sobrero et al 
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Figure 2 Kaplan–Meier PFS curve for all 105 patients 
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Figure 3 Kaplan–Meier survival curve for all 105 patients 
Table 3 Toxicity: worst WHO grade per patient across all cycles 
MTX®FU toxicity grade (%) n = 105 CIFU + 6-S-LV toxicity grade (%) n = 103 
Toxicity I II III IV I II III IV 
Mucositis 20 16 6 1 19 22 10 0 
Diarrhoea 7 10 2 1 5 8 4 0 
Nausea/vomiting 17 11 3 0 16 8 0 0 
Conjunctivitis 11 2 0 0 18 4 0 0 
Hand-foot syndrome 10 2 0 0 13 0 1 0 were reported following either part of the regimen. Stomatitis was
the most commonly observed severe side effect in both parts:
fewer than 7% of patients in the bolus part of the programme and
10% in the CI part. Grade IV toxicity was not reported during the
infusional part of the regimen. 
No prophylactic antiemetics were used during CI FU, while
either metoclopramide or metoclopramide plus steroids were used
during the first 3 days of the bolus schedule. 
Only 5 patients (5%) had catheter-related complications requir-
ing admission to hospital: 1 with sepsis and 3 with thrombosis. In
addition, 1 patient had the treatment changed following removal of
a damaged catheter. 
The cost of 3 cycles (median duration of treatment) of this
chemotherapy (6 months) in the Italian setting was calculated
assuming that no complication occurred, that the treatment was
done on an outpatient basis and that 7 accesses/cycle were neces-
sary. Such cost can be estimated to be $11400 US to which an
additional 1500 USD for the catheter and its implantation. This
may be compared to the recently reported regimen of FU + CPT-11
where the cost for the same length of treatment (12 biweekly
administrations = 6 months) adds up to $31 500 US plus the same
cost for catheter implantation, not counting the cost for the
management of the severe toxicities occurring in up to 36% and
46% of patients for diarrhoea and leukopenia, respectively
(Douillard et al, 2000). 
DISCUSSION 
The clinical research on CRC is now fully dominated by CPT-11,
oxaliplatin and the oral fluoropyrimidines. In addition, the novel
agents such as C-225 (Waksal, 1999), SU 5416 (Rosen et al, 2000),
RhuMabVEGF (Bergsland et al, 2000) and ONYX 0–15 (Reid 
et al, 2000) show their first signs of clinical activity in early 
phase II studies in this disease. Scheduling of FU, biochemical
modulation and mito therefore are certainly not ‘cutting edge’ clin-
ical research. Nevertheless, the present trial started 3 years ago
when the above ‘booming’ prospectives were still far away,
raltitrexed was the new big thing around, the novel agents were
confined to the preclinical world and our review on the importance
of FU scheduling was just published on a leading oncology journal
(Sobrero et al, 1997). The still very short life span of the results
obtained with CPT-11 and oxaliplatin combinations would suggest
to be more cautious, especially considering cost and toxicity. 
In the last 3 years we have published 3 clinical trials based upon
our hypothesis that FU is indeed 2 different drugs depending upon
the schedule of administration (Sobrero et al, 1995, 2000; Aschele
et al, 1998). If that hypothesis holds up in the clinic, maximal
enhancement of bolus FU is more likely obtained with drugs that
enhance the RNA effect of the fluoropyrimidine such as MTX,
while LV, that selectively enhances the TS inhibitory activity of
FU, may result in greater potentiation when the fluoropyrimidine
is administered as continuous infusion. In each of the 3 studies
done with this regimen, the response rate was always greater than
35%, the PFS and OS always longer than 6.5 and 15 months
respectively. When a British group (Ross et al, 1997) reported that
CI FU + mito was superior to CI FU alone in terms of response rate
and PFS (54% response rate, 7.9 months in PFS and 14 months in
OS were obtained in the combination arm), it seemed logical to us
to incorporate that low-cost drug into the infusional part of our
regimen. The response rate in our trial was not particularly high,
but the PFS and OS were the longest observed among our
multicentric studies on a total of more than 300 patients with
similar characteristics. 
It is obviously unfair to compare our phase II data with those of
the randomized British trial (the shorter OS in the British trial is
certainly explained by the randomized nature of their study),
however both studies suggest a renewed role for an old, cheap and
non-toxic (at these doses) agent in the treatment of this disease. 
The consistency of the results we have obtained throughout our
4 trials in this field makes us consider the results of this latest
phase II very encouraging, nevertheless we cannot propose this
regimen as standard first-line treatment because of the lack of
phase III data. 
Since toxicity affords, the logical next step is to incorporate the
new cytotoxics into this old style, but still very effective regimen.
Our ongoing trial in fact investigates the addition of oxaliplatin to
MTX ® FU bolus, leaving the infusional part unchanged. If this
regimen shows a substantial improvement in activity with toler-
able toxicity (say an additional 15–20% response rate, and a
concomitant further prolongation of PFS by a couple of months),
we will randomize our new regimen vs whatever combination will
be regarded as standard at that time. Should the benefit afforded by
the addition of oxaliplatin be more limited, we will instead
proceed to a new phase II incorporating CPT-11 into our schedule
specific regimen. 
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